TY - JOUR
T1 - Prognostic value of pre-transplantation total metabolic tumor volume on 18fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography in relapsed and refractory aggressive lymphoma
AU - Sugio, Takeshi
AU - Baba, Shingo
AU - Mori, Yasuo
AU - Yoshimoto, Goichi
AU - Kamesaki, Kenjiro
AU - Takashima, Shuichiro
AU - Urata, Shingo
AU - Shima, Takahiro
AU - Miyawaki, Kohta
AU - Kikushige, Yoshikane
AU - Kunisaki, Yuya
AU - Numata, Akihiko
AU - Takenaka, Katsuto
AU - Iawasaki, Hiromi
AU - Miyamoto, Toshihiro
AU - Ishigami, Kousei
AU - Akashi, Koichi
AU - Kato, Koji
N1 - Publisher Copyright:
© 2022, Japanese Society of Hematology.
PY - 2022/10
Y1 - 2022/10
N2 - Relapsed and refractory aggressive lymphoma have a poor prognosis. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is effective in chemosensitive patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is among the few options for non-chemosensitive patients. 18Fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography (18FDG-PET/CT) is the standard tool for evaluating response to chemotherapy and residual tumor volume. However, accurate assessment of residual tumor volume is not currently being achieved in clinical practice, and its value in prognostic and therapeutic stratification remains unclear. To answer this question, we investigated the efficacy of quantitative indicators, including total metabolic tumor volume (TMTV), in predicting prognosis after auto-HSCT and allo-HSCT. We retrospectively analyzed 39 patients who received auto-HSCT and 28 who received allo-HSCT. In the auto-HSCT group, patients with a higher TMTV had a poor prognosis due to greater risk of relapse. In the allo-HSCT group, patients with a higher TMTV had a lower progression-free survival rate and a significantly higher relapse rate. Neither Deauville score nor other clinical parameters were associated with prognosis in either group. Therefore, pre-transplant TMTV on PET is effective for prognostic prediction and therapeutic decision-making for relapsed or refractory aggressive lymphoma.
AB - Relapsed and refractory aggressive lymphoma have a poor prognosis. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) is effective in chemosensitive patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is among the few options for non-chemosensitive patients. 18Fluoro-2-deoxy-d-glucose positron emission tomography–computed tomography (18FDG-PET/CT) is the standard tool for evaluating response to chemotherapy and residual tumor volume. However, accurate assessment of residual tumor volume is not currently being achieved in clinical practice, and its value in prognostic and therapeutic stratification remains unclear. To answer this question, we investigated the efficacy of quantitative indicators, including total metabolic tumor volume (TMTV), in predicting prognosis after auto-HSCT and allo-HSCT. We retrospectively analyzed 39 patients who received auto-HSCT and 28 who received allo-HSCT. In the auto-HSCT group, patients with a higher TMTV had a poor prognosis due to greater risk of relapse. In the allo-HSCT group, patients with a higher TMTV had a lower progression-free survival rate and a significantly higher relapse rate. Neither Deauville score nor other clinical parameters were associated with prognosis in either group. Therefore, pre-transplant TMTV on PET is effective for prognostic prediction and therapeutic decision-making for relapsed or refractory aggressive lymphoma.
KW - Allogeneic transplantation
KW - Autologous transplantation
KW - Lymphoma
KW - PET/CT
KW - Tumor volume
UR - http://www.scopus.com/inward/record.url?scp=85131817885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131817885&partnerID=8YFLogxK
U2 - 10.1007/s12185-022-03394-w
DO - 10.1007/s12185-022-03394-w
M3 - Article
C2 - 35701707
AN - SCOPUS:85131817885
SN - 0925-5710
VL - 116
SP - 603
EP - 611
JO - International journal of hematology
JF - International journal of hematology
IS - 4
ER -